Radiopharmaceutical provider IBA Molecular and Piramal Imaging have announced an agreement under which IBA will manufacture and distribute F-18 florbetaben, Piramal's new diagnostic imaging agent, in the European and U.S. markets.
F-18 florbetaben is a radiopharmaceutical being developed for use with PET to detect beta-amyloid plaque deposits in the brain, a pathological feature associated with Alzheimer's disease and other neurologic conditions, according to the companies.
Piramal recently acquired the intellectual property, worldwide development, and marketing and distribution rights of the lead compound for F-18 florbetaben, as well as other clinical and preclinical assets of the molecular imaging business from Bayer HealthCare Pharmaceuticals to form its imaging subsidiary, Piramal Imaging.
